Highly Reproducible Quantitative Proteomics Analysis of Pancreatic Cancer Cells Reveals Proteome-Level Effects of a Novel Combination Drug Therapy That Induces Cancer Cell Death via Metabolic Remodeling and Activation of the Extrinsic Apoptosis Pathway

Biomarker Candidates for Tumors Identified from Deep-Profiled Plasma Stem Predominantly from the Low Abundant Area

(2022) Marco Tognetti et al.   JOURNAL OF PROTEOME RESEARCH

Comparative Proteomic Analysis Identifies Key Metabolic Regulators of Gemcitabine Resistance in Pancreatic Cancer

(2022) Qingxiang Lin et al.   MOLECULAR & CELLULAR PROTEOMICS

High-quality and robust protein quantification in large clinical/pharmaceutical cohorts with IonStar proteomics investigation

(2022) Shichen Shen et al.   Nature Protocols

Cancer Statistics, 2021

(2021) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Synergistic pharmacodynamic effects of gemcitabine and fibroblast growth factor receptor inhibitors on pancreatic cancer cell cycle kinetics and proliferation

(2021) Qingxiang Lin et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study

(2021) Milind Javle et al.   Lancet Gastroenterology & Hepatology

Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma

(2020) P. G. Corrie et al.   BRITISH JOURNAL OF CANCER

Implications of HIF-1α in the tumorigenesis and progression of pancreatic cancer

(2020) Xiao Jin et al.   Cancer Cell International

Mitochondrial Metabolism in PDAC: From Better Knowledge to New Targeting Strategies

(2020) Gabriela Reyes-Castellanos et al.   Biomedicines

Mutant Kras as a Biomarker Plays a Favorable Role in FL118-Induced Apoptosis, Reactive Oxygen Species (ROS) Production and Modulation of Survivin, Mcl-1 and XIAP in Human Bladder Cancer

(2020) Sreevidya Santha et al.   Cancers

Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?

(2019) Ursula M. Vogl et al.   BMC CANCER

Chemotherapy for pancreatic cancer

(2019) Christoph Springfeld et al.   PRESSE MEDICALE

MS1 ion current‐based quantitative proteomics: A promising solution for reliable analysis of large biological cohorts

(2019) Xue Wang et al.   MASS SPECTROMETRY REVIEWS

Glycolytic suppression dramatically changes the intracellular metabolic profile of multiple cancer cell lines in a mitochondrial metabolism-dependent manner

(2019) Reika Shiratori et al.   Scientific Reports

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma

(2018) Milind Javle et al.   JOURNAL OF CLINICAL ONCOLOGY

IonStar enables high-precision, low-missing-data proteomics quantification in large biological cohorts

(2018) Xiaomeng Shen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations

(2018) Sumanta K. Pal et al.   Cancer Discovery

Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells

(2018) A. M. Gravett et al.   OncoImmunology

Surfactant Cocktail-Aided Extraction/Precipitation/On-Pellet Digestion Strategy Enables Efficient and Reproducible Sample Preparation for Large-Scale Quantitative Proteomics

(2018) Shichen Shen et al.   ANALYTICAL CHEMISTRY

Tumor suppressive role for kinases phosphorylating p53 in the DNA damage-induced apoptosis

(2018) Satomi Yogosawa et al.   CANCER SCIENCE

An IonStar Experimental Strategy for MS1 Ion Current-Based Quantification Using Ultrahigh-Field Orbitrap: Reproducible, In-Depth, and Accurate Protein Measurement in Large Cohorts

(2017) Xiaomeng Shen et al.   JOURNAL OF PROTEOME RESEARCH

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

(2017) John P Neoptolemos et al.   LANCET

Metabolic coupling and the Reverse Warburg Effect in cancer: Implications for novel biomarker and anticancer agent development

(2017) Lindsay Wilde et al.   SEMINARS IN ONCOLOGY

Bisphenol A induces cell cycle arrest in primary and prostate cancer cells through EGFR/ERK/p53 signaling pathway activation

(2017) Antonio Bilancio et al.   Oncotarget

The reverse Warburg effect is likely to be an Achilles’ heel of cancer that can be exploited for cancer therapy

(2017) Yaojie Fu et al.   Oncotarget

Combination therapy in combating cancer

(2017) Reza Bayat Mokhtari et al.   Oncotarget

The urgent need to recover MHC class I in cancers for effective immunotherapy

(2016) Federico Garrido et al.   CURRENT OPINION IN IMMUNOLOGY

Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?

(2016) Marie de Charette et al.   EUROPEAN JOURNAL OF CANCER

Expression of Death Receptor 4 Is Positively Regulated by MEK/ERK/AP-1 Signaling and Suppressed upon MEK Inhibition

(2016) Weilong Yao et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Low-dose gemcitabine induces major histocompatibility complex class I-related chain A/B expression and enhances an antitumor innate immune response in pancreatic cancer

(2015) Tomoharu Miyashita et al.   CLINICAL AND EXPERIMENTAL MEDICINE

Metabolic modulation of cancer: a new frontier with great translational potential

(2015) Adam Kinnaird et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Experimental Null Method to Guide the Development of Technical Procedures and to Control False-Positive Discovery in Quantitative Proteomics

(2015) Xiaomeng Shen et al.   JOURNAL OF PROTEOME RESEARCH

Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence

(2014) A. R. de Biasi et al.   CLINICAL CANCER RESEARCH

Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models

(2013) H Zhang et al.   BRITISH JOURNAL OF CANCER

Gemcitabine Plus Erlotinib for Advanced Pancreatic Cancer: A Systematic Review with Meta-Analysis

(2013) Zu-Yao Yang et al.   PLoS One

Fibroblast Growth Factor Receptors as Novel Therapeutic Targets in SNF5-Deleted Malignant Rhabdoid Tumors

(2013) Simon Wöhrle et al.   PLoS One

Discovery of 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase

(2011) Vito Guagnano et al.   JOURNAL OF MEDICINAL CHEMISTRY

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fatty acid synthase as a potential therapeutic target in cancer

(2010) Richard Flavin et al.   Future Oncology

Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses

(2009) W M Liu et al.   BRITISH JOURNAL OF CANCER

Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources

(2009) Da Wei Huang et al.   Nature Protocols

Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation

(2009) M. G. Vander Heiden et al.   SCIENCE

ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes

(2008) Jiahao Liu et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Exposure of any of two proapoptotic domains of presenilin 1-associated protein/mitochondrial carrier homolog 1 on the surface of mitochondria is sufficient for induction of apoptosis in a Bax/Bak-independent manner

(2008) V LAMARCA et al.   EUROPEAN JOURNAL OF CELL BIOLOGY